Caris Life Sciences to present CapeAI study predicting capecitabine response in ER+ breast cancer at ESMO 2026
CAI•Caris Life Sciences plans to present eight AI-driven oncology studies at the ESMO Congress in Madrid on Oct. 23–27, 2026; two Caris-led studies focus on breast cancer treatment selection.
1. Studies scheduled for October
Caris Life Sciences flagged eight AI-driven precision-oncology studies for presentation at the ESMO Congress 2026 in Madrid. Results have not yet been presented; posters are scheduled for Oct. 23–27, with Caris-led sessions on Oct. 25. Two Caris-led studies aim to predict capecitabine response and risk and stratify endocrine-therapy benefit in breast cancer.
